BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 25305095)

  • 41. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.
    Tashakori M; Khoury JD; Routbort MJ; Patel KP; Wang SA; Ok CY; El-Hussein S; Kanagal-Shamanna R; Luthra R; Hu S; Lin P; Pemmaraju N; Bose P; Verstovsek S; Bueso-Ramos CE; Medeiros LJ; Loghavi S
    Mod Pathol; 2022 Nov; 35(11):1677-1683. PubMed ID: 35690645
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The 2016 WHO versus 2008 WHO Criteria for the Diagnosis of Chronic Myelomonocytic Leukemia.
    Moon Y; Kim MH; Kim HR; Ahn JY; Huh J; Huh JY; Han JH; Park JS; Cho SR
    Ann Lab Med; 2018 Sep; 38(5):481-483. PubMed ID: 29797820
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.
    McCullough KB; Patnaik MM
    Curr Hematol Malig Rep; 2015 Sep; 10(3):292-302. PubMed ID: 26122388
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice.
    Patnaik MM; Tefferi A
    Mayo Clin Proc; 2016 Feb; 91(2):259-72. PubMed ID: 26848006
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing.
    Komeno Y; Huang YJ; Qiu J; Lin L; Xu Y; Zhou Y; Chen L; Monterroza DD; Li H; DeKelver RC; Yan M; Fu XD; Zhang DE
    Mol Cell Biol; 2015 Sep; 35(17):3071-82. PubMed ID: 26124281
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.
    Muramatsu H; Makishima H; Maciejewski JP
    Semin Oncol; 2012 Feb; 39(1):67-73. PubMed ID: 22289493
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
    Palomo L; Garcia O; Arnan M; Xicoy B; Fuster F; Cabezón M; Coll R; Ademà V; Grau J; Jiménez MJ; Pomares H; Marcé S; Mallo M; Millá F; Alonso E; Sureda A; Gallardo D; Feliu E; Ribera JM; Solé F; Zamora L
    Oncotarget; 2016 Aug; 7(35):57021-57035. PubMed ID: 27486981
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.
    Hamilton BK; Visconte V; Jia X; Tabarroki A; Makishima H; Hasrouni E; Abounader D; Kalaycio M; Sekeres MA; Sobecks R; Duong Liu H; Bolwell B; Maciejewski JP; Copelan E; Tiu RV
    Am J Hematol; 2016 Jun; 91(4):406-9. PubMed ID: 26799334
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Our experience with detection of JAK2 mutations in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative disorders].
    Burjanivová T; Marcinek J; Minárik G; Lasabová Z; Szépe P; Balhárek T; Vanochová A; Plank L
    Cesk Patol; 2011 Jul; 47(3):115-7. PubMed ID: 21887928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent Updates on Chronic Myelomonocytic Leukemia.
    Loghavi S; Khoury JD
    Curr Hematol Malig Rep; 2018 Dec; 13(6):446-454. PubMed ID: 30311069
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia.
    Hwang SM; Kim SM; Nam Y; Kim J; Kim S; Ahn YO; Park Y; Yoon SS; Shin S; Kwon S; Lee DS
    Leuk Res; 2019 Sep; 84():106190. PubMed ID: 31377458
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?
    Michaux JL; Martiat P
    Leuk Lymphoma; 1993 Jan; 9(1-2):35-41. PubMed ID: 8477199
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature.
    Guastafierro V; Ubezio M; Manes N; Milanesi C; Della Porta M; Bonometti A
    Leuk Lymphoma; 2023 Sep; 64(9):1566-1573. PubMed ID: 37395413
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
    Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
    Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronic myelomonocytic leukemia: The role of bone marrow biopsy immunohistology.
    Orazi A; Chiu R; O'Malley DP; Czader M; Allen SL; An C; Vance GH
    Mod Pathol; 2006 Dec; 19(12):1536-45. PubMed ID: 17041567
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia.
    Hurtado AM; Luengo-Gil G; Chen-Liang TH; Amaral F; Batta K; Palomo L; Lumbreras E; Przychodzen B; Caparros E; Amigo ML; Dıez-Campelo M; Zamora L; Salido Fierrez EJ; Maciejewski JP; Ortuño FJ; Vicente V; Del Canizo M; Sole F; Ferrer-Marin F; Wiseman DH; Jerez A
    Br J Haematol; 2018 Aug; 182(3):373-383. PubMed ID: 29797327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
    Qian Y; Chen Y; Li X
    Ann Hematol; 2021 Jun; 100(6):1459-1461. PubMed ID: 33822276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities.
    Zhang J; Lieu YK; Ali AM; Penson A; Reggio KS; Rabadan R; Raza A; Mukherjee S; Manley JL
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):E4726-34. PubMed ID: 26261309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
    Hall J; Foucar K
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
    Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.